| Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA | Ben Fidler | 08/26/16 | National |
| Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More | Alex Lash | 07/29/16 | National |
| Sarepta Stock Down as FDA Seeks More Data from Rival Duchenne Drug | Frank Vinluan | 07/14/16 | Boston |
| Two Years After Paying $680M, BioMarin Shelves Duchenne Drug | Ben Fidler | 05/31/16 | San Francisco |
| Sarepta Saga Drags On as FDA Delays Decision on Duchenne Drug | Ben Fidler | 05/25/16 | Boston |
| Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote | Ben Fidler | 04/25/16 | Boston |
| East Coast Biotech Roundup: Harvard’s Haul, Patent Fights, Padlock & More | Ben Fidler | 03/24/16 | Boston |
| Startups Begin to Emerge From NYU’s “Virtual” Biotech Factory | Ben Fidler | 03/17/16 | New York |
| East Coast Biotech Roundup: Ribon, Syndax, Aldeyra & More | Ben Fidler | 03/03/16 | Boston |
| Déjà Vu for PTC as FDA Declines to Consider Duchenne Drug App | Ben Fidler | 02/23/16 | New York |
| Safety Issues Spur Foundation-Backed Akashi to Suspend Duchenne Trial | Ben Fidler | 01/26/16 | Boston |
| At Duchenne Panel, Parents Plead With Experts, FDA Decision Looms | Ben Fidler | 11/24/15 | San Francisco |
| East Coast Biotech Roundup: Zafgen, Decibel, Voyager & More | Ben Fidler | 10/16/15 | Boston |
| PTC Unveils Mixed Duchenne Results, But Plots an FDA Filing | Ben Fidler | 10/15/15 | New York |
| After Shift to Duchenne and Cholesterol Drugs, Catabasis Files For IPO | Ben Fidler | 05/14/15 | Boston |
| Dallas’ AveXis Gets $10M to Bring Gene Therapy to Rare Spinal Disorder | Angela Shah | 01/20/15 | Texas |
| BioMarin Gambles $840M on Prosensa’s Duchenne Drug | Ben Fidler | 11/24/14 | San Francisco |
| East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More | Ben Fidler | 05/27/14 | Boston |
| Navigating JOBS, Wrangling Investors: A Biotech CFO Roundtable | Alex Lash | 05/27/14 | National |
| EU Reverses Course on PTC Drug, Shares Boom | Ben Fidler | 05/23/14 | New York |
| East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More | Ben Fidler | 01/24/14 | Boston |
| Sarepta Shares Crumble As FDA Calls New Drug Application “Premature” | Ben Fidler | 11/12/13 | Boston |
| Sarepta to Seek FDA Approval For Duchenne Muscular Dystrophy Drug | Ben Fidler | 07/24/13 | Boston |
| NY Editor’s Picks: Xconomy Stories That Got This City Talking in Q2 | João-Pierre S. Ruth | 07/03/13 | New York |
| East Coast Life Sciences Roundup: IPO Madness, Amicus, & More | Ben Fidler | 06/21/13 | Boston |
| PTC Therapeutics IPO Raises $125M Despite Checkered Past | Ben Fidler | 06/20/13 | New York |
| East Coast Life Sciences Roundup: ASCO, Follica, Aveo, & More | Ben Fidler | 06/07/13 | Boston |
| East Coast Life Sciences Roundup: Merck, Celgene, PTC, Cerulean | Bernadette Tansey | 03/08/13 | Boston |
| Sarepta Drug Helps Boys With Duchenne to Walk; Shares Boom | Luke Timmerman | 10/03/12 | Boston |
| Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says | Luke Timmerman | 02/01/12 | Boston |
